Oxford Vacmedix

Beyond Just Peptide Antigens: The complex world of peptide-based cancer vaccines

Therapeutic vaccines may well be the next wave of immunotherapy for cancer treatment. Peptide-based vaccines will play a pivotal role in the field. How is a peptide vaccine designed? What other factors such as adjuvants etc should be considered? Can Immunol oncological agents be synergetic with peptide vaccines? Read the full article: Beyond Just Peptide Antigens: The complex world of peptide-based cancer vaccines By Alexander J Stephens, Nicola A Burgess-Brown and Shisong Jiang Publisehd in Fro...
Read More

Mark Thomas appointed as Head of Clinical Operations

Oxford Vacmedix UK Ltd announces the appointment of Mark Thomas as Head of Clinical Operations, bringing in-depth expertise in running clinical trials and in pharmaceutical development to Oxford Vacmedix. Press Release – appointment of Mark Thomas as Head of Clinical Operations Oxford, 14th June 2021: Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today the appointment of Mark Thomas as the Head of Clinical Operations. He was previou...
Read More

Dr Thomas Morris appointed as Chief Medical Officer

Oxford Vacmedix UK Ltd announces the appointment of Dr Thomas Morris as Chief Medical Officer, bringing in-depth expertise in oncology clinical development to the Company. Press Release – Dr Thomas Morris appointed as Chief Medical Officer Oxford, 23rd March 2021: Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today the appointment of Dr. Thomas Morris BSc, MB BCh, LlM, MRCP FFPM as Chief Medical Officer.  Tom originally worked as a...
Read More

Oxford Vacmedix and CHAIN Biotech collaborate to develop oral vaccines

Oxford Vacmedix and CHAIN Biotech have signed Heads of Terms for a Collaboration Agreement to develop and commercialise oral vaccines targeting cancer & infectious disease Oxford, UK – 4th January 2020 – FOR IMMEDIATE RELEASE Press Release – OVM CHAIN Collaboration Oxford 4th Jan 2020; Oxford Vacmedix (OVM), the UK based biopharma company, focused on the development of a new generation of cancer vaccines, announced today that Heads of Terms for a Collaboration Agreement have been s...
Read More

Oxford Vacmedix announces filing of new patent for Covid-19 vaccine and diagnostics

New patent using Recombinant Overlapping Peptide (ROP technology) as novel approach to SARS-Cov-2 pandemic filed, after rapid development and initial testing Oxford, UK – 24th November 2020 – FOR IMMEDIATE RELEASE Press Release-Patent filed for Covid-19 vaccine and diagnostics 24-11-20 Oxford 24th November 2020; Oxford Vacmedix (OVM), the UK based biopharma company, focused on the development of a new generation of cancer vaccines, announced today that research work on Covid-19 started earli...
Read More

Oxford Vacmedix founder Dr Shisong Jiang appointed as Senior Industrial Fellow at University of Oxford

Shisong Jiang is appointed to the newly created role of Senior Industrial Fellow in the Department of Oncology at the University of Oxford Oxford, UK – 9th November 2020 – FOR IMMEDIATE RELEASE Download PDF – Press Release-Senior Industrial Fellow 09-11-20 Oxford 9th November 2020; Oxford Vacmedix (OVM), the UK based biopharma company, focused on the development of a new generation of cancer vaccines, announced today that the founder of the company, Dr. Shisong Jiang, has been appointe...
Read More

Oxford Vacmedix announces collaboration to develop vaccine and diagnostic tests for Covid-19

Collaboration with the Nuffield Department of Medicine, University of Oxford will use recombinant overlapping peptide technology to develop a novel vaccine and diagnostic tests for Covid-19 Press Release Covid-19 project 12 May 2020 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focusing on the development of cancer vaccines, announced today that it will use its proprietary recombinant overlapping peptide (ROP) technology to develop a new vaccine and diagnostic tests for Covid-...
Read More

Comparing Pooled Peptides with Intact Protein for Accessing Cross-presentation Pathways for Protective CD8 and CD4 T Cells

Zhang et al – 2009 (view in PDF)...
Read More

Mouse Model for Pre-Clinical Study of Human Cancer Immunotherapy

Ya Z. et al – 2015 (view in PDF)...
Read More

WHO guidelines on nonclincial evaluation of vaccines

WHO Guideline – nonclinical_evaluation_vaccines_nov_2003...
Read More
en_GBEnglish